VALIDATION IMAGES
Lane 1: Hela cell lysates; Lane 2: CD44 knockout (KO) HeLa cell lysates probed with CD44 Polyclonal Antibody, Unconjugated (bs-55039R) at 1:1000 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.
Lane 1: Mouse spleen cell lysates probed with CD44 Polyclonal Antibody, Unconjugated (bs-55039R) at 1:1000 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.
Lane 1: Human A549 cell lysates; Lane 2: Human U2os cell lysates; Lane 3: Human MDA-MB-231 cell lysates; Lane 4: Human Hela cell lysates probed with CD44 Polyclonal Antibody, Unconjugated (bs-55039R) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.
Lane 1: Human Hela cell (Control) lysates; Lane 2: CD44 knockout (KO) Hela cell lysates probed with CD44 Polyclonal Antibody, Unconjugated (bs-55039R) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.
Lane 1: Human Hela cell lysates; Lane 2: Human Panc-1 cell lysates; Lane 3: Human Huvec cell lysates; Lane 4: Human A549 cell lysates probed with CD44 Polyclonal Antibody, Unconjugated (bs-55039R) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at room temperature for 60 min.